The Yuan requests your support! Our content will now be available free of charge for all registered subscribers, consistent with our mission to make AI a human commons accessible to all. We are therefore requesting donations from our readers so we may continue bringing you insightful reportage of this awesome technology that is sweeping the world. Donate now
AI supercharges biomarker-driven clinical trials, raises accuracy, success
By Andrii Buvailo  |  Sep 20, 2023
AI supercharges biomarker-driven clinical trials, raises accuracy, success
Image courtesy of and under license from
Clinical trials are key in testing new treatments and their suitability for widespread use. AI is already making drug discovery cheaper and more efficient, and is now boosting clinical trials’ success. Pharma analyst and co-founder Andrii Buvailo reports.

VALENCIA, SPAIN - Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving treatments for patients. 

Unfortunately, the success rate of clinical trials - particularly in the field of oncology - is not as robust as one might hope. A 2019 study of 7,455 interventional phase trials in oncology conducted from 2000 to 2015 suggests only 3.4 percent of cancer drugs that enter Phase I clinical trials ultimately receive approval from the United States Food and Drug Administration (FDA). Many of these failures are attributable to obstacles such as poor trial design and inefficient patient selection, which often result from a lack of biomarker-driven insights. As a result, drug development can be laborious and expensive, with the estimated cost of bringing a new drug to market around USD2.6 billion. As the world grapples with these challenges, calls for more efficient and targeted methods of drug development become more urgent. The answer for achieving this may lie in the utilization of novel actionable biomarkers and the power of artificial intelligence (AI) to plan and execute clinical trials. 

IQVIA's AI-based platform shows how this works using its real-world data to enable more precise targeting of patients and healthcare professionals. Compared to prior traditional methods, this has doubled the number of identified eligible patients, found 30 percent more with uncontrolled symptoms, predicted 81 percent of those likely to quit treatment early, pinpointed events linked to early discontinuation, and boosted treatment transition success rates fivefold.

The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.
Continue reading
Sign up now to read this story for free.
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.